Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 2
2019 1
2020 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Results by year

Filters applied: . Clear all
Page 1
Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity.
Kotanides H, Sattler RM, Lebron MB, Carpenito C, Shen J, Li J, Surguladze D, Haidar JN, Burns C, Shen L, Inigo I, Pennello AL, Forest A, Chen X, Chin D, Sonyi A, Topper M, Boucher L, Sharma P, Zhang Y, Burtrum D, Novosiadly RD, Ludwig DL, Plowman GD, Kalos M. Kotanides H, et al. Among authors: sonyi a. Mol Cancer Ther. 2020 Apr;19(4):988-998. doi: 10.1158/1535-7163.MCT-19-0893. Mol Cancer Ther. 2020. PMID: 32241872
Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity.
Kotanides H, Li Y, Malabunga M, Carpenito C, Eastman SW, Shen Y, Wang G, Inigo I, Surguladze D, Pennello AL, Persaud K, Hindi S, Topper M, Chen X, Zhang Y, Bulaon DK, Bailey T, Lao Y, Han B, Torgerson S, Chin D, Sonyi A, Haidar JN, Novosiadly RD, Moxham CM, Plowman GD, Ludwig DL, Kalos M. Kotanides H, et al. Among authors: sonyi a. Cancer Immunol Res. 2020 Oct;8(10):1300-1310. doi: 10.1158/2326-6066.CIR-20-0304. Epub 2020 Jul 27. Cancer Immunol Res. 2020. PMID: 32873605
Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054.
Li Y, Carpenito C, Wang G, Surguladze D, Forest A, Malabunga M, Murphy M, Zhang Y, Sonyi A, Chin D, Burtrum D, Inigo I, Pennello A, Shen L, Malherbe L, Chen X, Hall G, Haidar JN, Ludwig DL, Novosiadly RD, Kalos M. Li Y, et al. Among authors: sonyi a. J Immunother Cancer. 2018 Apr 30;6(1):31. doi: 10.1186/s40425-018-0329-7. J Immunother Cancer. 2018. PMID: 29712568 Free PMC article.
The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy.
Schaer DA, Geeganage S, Amaladas N, Lu ZH, Rasmussen ER, Sonyi A, Chin D, Capen A, Li Y, Meyer CM, Jones BD, Huang X, Luo S, Carpenito C, Roth KD, Nikolayev A, Tan B, Brahmachary M, Chodavarapu K, Dorsey FC, Manro JR, Doman TN, Donoho GP, Surguladze D, Hall GE, Kalos M, Novosiadly RD. Schaer DA, et al. Among authors: sonyi a. Clin Cancer Res. 2019 Dec 1;25(23):7175-7188. doi: 10.1158/1078-0432.CCR-19-0433. Epub 2019 Aug 13. Clin Cancer Res. 2019. PMID: 31409612
Correction to: Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054.
Li Y, Carpenito C, Wang G, Surguladze D, Forest A, Malabunga M, Murphy M, Zhang Y, Sonyi A, Chin D, Burtrum D, Inigo I, Pennello A, Shen L, Malherbe L, Chen X, Hall G, Haidar JN, Ludwig DL, Novosiadly RD, Kalos M. Li Y, et al. Among authors: sonyi a. J Immunother Cancer. 2018 Jun 4;6(1):45. doi: 10.1186/s40425-018-0354-6. J Immunother Cancer. 2018. PMID: 29866166 Free PMC article.